In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...
The U.S. FDA's approval Thursday of BristolMyers Squibb's (NYSE:BMY) novel antipsychotic Cobenfy (xanomeline and trospium chloride) for schizophrenia could significant influence treatment of ...
BMO Capital analyst notes that the FDA approval without a boxed warning is a significant positive for BristolMyers shares. The analyst notes that given that many prior antipsychotic medications ...
2seventy bio and BristolMyers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma. 2seventy on ...
Results that may be inaccessible to you are currently showing.